Chief Judge Daniel Domenico of the Denver federal court granted Amgen a preliminary injunction on Wednesday. The ruling blocks Colorado from implementing a first-in-the-nation price cap on the arthritis drug Enbrel.
This decision halts the state's Prescription Drug Affordability Board from enforcing limits scheduled for January 2027. Judge Domenico ruled that Amgen would likely face irreparable harm and disrupted contract negotiations.
Amgen argued the Colorado law conflicts with federal patent law and violates constitutional due process rights. The ruling represents a setback for states attempting to control prescription costs and may influence similar national efforts.